Luminex (LMNX) Well Above-Consensus Profit; Deutsche Bank Sees Upside In Stryker (SYK)

Luminex_LMNX

Shares of Luminex Corp. (Nasdaq:LMNX) climbed more than 5% in the extended session Monday after the company delivered quarterly profit numbers well-above analysts’ expectations

For the fourth quarter 2015, Luminex posted revenue of $60.4 million, a 4% increase year over year, and non-GAAP net income of $24.1 million, or $0.56 per diluted share, easily surpassing the Capital IQ Consensus estimate of $0.13 earnings per share and also topping the $60.22 million in revenue expected by Wall Street’s analysts for the period

LMNX stock closed at $18.87, down $0.32 (or -1.67%), with a total volume of 297,199 shares traded during the day

Luminex, which develops, manufactures, and sells proprietary biological testing technologies and products, has 43.06M Shares Outstanding, Market Capitalization (intraday) of $812.58M and LMNX stock 52-week range is between $15.05 and $22.85 per share

*

Stryker_SYK

Investment analysts at Deutsche Bank raised their price target on shares of Stryker Corp. (NYSE:SYK) from $107.00 to $113.00, while maintaining a Buy rating

SYK stock finished the regular session at $99.17, up $0.02 (or +0.02%), and 2,575,792 of its shares exchanged hands on Monday’s trading activity

Stryker, a medical technology company, has 376.00M Shares Outstanding, Market Capitalization (intraday) of $37.29B and SYK stock one-year range is from $86.68 to $105.34 per share

**

Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at http://galaxystocks.com/disclaimer/